This study is looking at sepsis, a serious condition that occurs when the body has an extreme response to an infection. Sepsis can affect both children and adults and may lead to organ failure and the need for life support treatments such as machines to help with breathing, medications to support blood pressure, or treatments to help the kidneys work. The study will test several different medications to see which ones might work better for different patients with sepsis. The medications being tested include hydrocortisone, anakinra, tocilizumab, human plasma protein, interferon gamma, baricitinib, heparin, dalteparin sodium, fludrocortisone acetate, and filgrastim. Some of these medications are given through a vein, some are injected under the skin, and some are taken by mouth or through a feeding tube.
The purpose of this study is to explore how well these different treatments work compared to usual care for sepsis and to provide information that can help doctors understand which treatments might be most helpful for different patients. The study will look at whether patients survive and how many days they are able to live without needing life support treatments such as breathing machines, blood pressure medications, or kidney support within 28 days after starting the study. This information will help researchers develop ideas for future studies that can confirm which treatments work best.
During the study, patients with sepsis will be assigned to receive one of the study medications or usual care. The study will follow patients for up to three years to see how they recover. Researchers will measure survival at different time points, how many days patients spend in the hospital, how long it takes for patients to walk without help again, when they can return to their normal activities, and their quality of life. The study uses a special design that allows researchers to compare different treatments at the same time and adjust the study as new information becomes available.
France 